Search Results
You are looking at 1 - 1 of 1 items for
- Author: R. P. Gooding x
- Refine by access: All content x
Search for other papers by A. F. Bristow in
Google Scholar
PubMed
Search for other papers by R. P. Gooding in
Google Scholar
PubMed
Search for other papers by R. E. Gaines Das in
Google Scholar
PubMed
ABSTRACT
Three preparations of recombinant DNA-derived insulin-like growth factor-I (IGF-I) were obtained, prepared in ampoules coded 86/522, 86/720 or 87/518, and evaluated as candidate International Reference Reagents in an international collaborative study (nine laboratories in four countries) in response to a request by the World Health Organization (WHO).
Immunoassay dose–response curves for each of the three preparations did not in general differ significantly from those of local standards or from those of ampouled preparations of serum-derived IGF-I which were included in the study. The estimates of ampoule contents in terms of local standards showed considerable heterogeneity; the between-laboratory variability of estimates in terms of local standards was ten times greater than the inherent variability of estimates from these systems as estimated from comparisons of coded duplicates. Bioassay data were limited, and those available were inconsistent with immunoassay data. Of the three preparations, ampoules coded 86/720 were derived from an IGF-I preparation that was heterogeneous by high-performance liquid chromatography, and stability data for the preparation 86/522 were anomalous.
As a result, the ampouled preparation coded 87/518 has been established by WHO as the International Reference Reagent for IGF-I for immunoassay, with an assigned ampoule content of 3·1 μg/ampoule, and is available from the National Institute for Biological Standards and Control.
Journal of Endocrinology (1990) 125, 191–197
